Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HRH2 | P25021 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25460713 | 0.83 | FDPS (0.49) | PKMFDPSHRH3KDM4EPOLB | |
| SCHEMBL22601646 | 0.78 | FDPS (0.45) | PKMFDPSHRH3KDM4EPOLB | |
| SCHEMBL28813959 | 0.77 | PKM (0.52) | PKMFDPSHRH3KDM4EPOLB | |
| SCHEMBL26437620 | 0.75 | HRH3 (0.58) | PKMFDPSHRH3HRH4 | |
| SCHEMBL226696 | 0.75 | TAAR1 (0.51) | HRH3HRH4 | |
| SCHEMBL5692256 | 0.75 | FDPS (0.54) | PKMFDPSHRH3KDM4EPOLB | |
| SCHEMBL2264740 | 0.74 | ARG1 (0.53) | PKMFDPSHRH3KDM4EPOLB | |
| SCHEMBL233717 | 0.73 | — | — | |
| SCHEMBL128969 | 0.73 | — | — | |
| SCHEMBL23983601 | 0.73 | HRH3 (0.54) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| EP-2091937-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2083822-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7524850-B2 | 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; serine/threonine protein kinase; antiproliferative | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051404-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | PKM 2151/4885FDPS 1363/4885HRH3 664/4885 |
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | PKM 3811/4885FDPS 3442/4885HRH3 1809/4885 |
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | PKM 1342/4885FDPS 48/4885HRH3 4313/4885 |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | MSN, AURKA, AURKC | PKM 4026/4885FDPS 3951/4885HRH3 1183/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | PKM 928/4885FDPS 1426/4885HRH3 3018/4885 |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | PKM 3241/4885FDPS 3547/4885HRH3 2483/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | PKM 2019/4885FDPS 1081/4885HRH3 862/4885 |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | ENTPD5, ENTPD1, NT5E | PKM 3098/4885FDPS 755/4885HRH3 2251/4885 |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | PKM 4026/4885FDPS 3951/4885HRH3 1183/4885 |
| US-20070142388-A1 | Inhibitors of Akt activity | AKT2, AKT1, AKT3 | PKM 1090/4885FDPS 1811/4885HRH3 4096/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | PKM 4005/4885FDPS 4360/4885HRH3 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.